Cargando…

The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Li, Jing-Xin, Zhu, Feng-Cai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015641/ https://www.ncbi.nlm.nih.gov/pubmed/35447084 http://dx.doi.org/10.1016/S1473-3099(22)00162-1

Ejemplares similares

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
por: Smolenov, Igor, et al.
Publicado: (2022)

Risk of SARS-CoV-2 reinfection after natural infection
por: Boyton, Rosemary J, et al.
Publicado: (2021)

SARS-CoV-2 reinfection in a closed setting: lessons for the community
por: Velasco, María, et al.
Publicado: (2021)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
por: Yang, Su Lan, et al.
Publicado: (2022)

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study
por: Buntinx, Erik, et al.
Publicado: (2023)

Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
por: Li, Jing-Xin, et al.
Publicado: (2021)

Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study
por: Hosain, Romana, et al.
Publicado: (2023)

SARS-Cov-2 immune waning and reinfection in care-home settings
por: Altmann, Daniel M, et al.
Publicado: (2021)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Reinfection With SARS-CoV-2: Implications for Vaccines
por: Cohen, Jeffrey I, et al.
Publicado: (2020)

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
por: Ambrosino, Donna, et al.
Publicado: (2021)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

SARS-CoV-2 reinfection()
por: Romera, I., et al.
Publicado: (2021)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

Trimeric S protein COVID-19 vaccine needs to find its place
por: Vesikari, Timo
Publicado: (2022)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine
por: Kennedy, Richard B
Publicado: (2022)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

SARS-CoV-2 and HIV-1 — a tale of two vaccines
por: Haynes, Barton F.
Publicado: (2021)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world
por: Garg, Pramod Kumar, et al.
Publicado: (2022)

Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease
por: Gao, Xing-Su, et al.
Publicado: (2022)

What reinfections mean for COVID-19
por: Iwasaki, Akiko
Publicado: (2021)

Reinfection and reactivation of SARS-CoV-2
por: Dowran, Razieh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9sp0b8fi56iqeev9j0vp52b26j